Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Onconova Therapeutic (ONTX)

Onconova Therapeutic (ONTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022 Globe Newswire - Thu Aug 4, 2022

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Announces Key Management Promotions Globe Newswire - Mon Jun 13, 2022

Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models Globe Newswire - Thu May 26, 2022

In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Wed May 11, 2022

Conference call and live webcast at 4:30 p.m. ET today...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting Globe Newswire - Wed Apr 27, 2022

NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit Globe Newswire - Wed Mar 23, 2022

NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update Globe Newswire - Thu Mar 17, 2022

Conference call and live webcast at 4:30 p.m. ET today...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022 Globe Newswire - Thu Mar 10, 2022

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference Globe Newswire - Tue Jan 4, 2022

NEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development Globe Newswire - Mon Dec 13, 2021

NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)

Barchart Exclusives

Dividend Aristocrats: The Best of the Best for Stable Income Barchart - Wed Sep 18, 2:16PM CDT
Dividend Aristocrats' ability to increase their dividends indicates strong earnings and a solid business foundation, which lowers investment risk. Moreover, their consistent earnings growth often enables them to outperform broader market indices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot